BA
MRNA icon

Bristlecone Advisors’s Moderna MRNA Stock Holding History

Bristlecone Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,239
Closed -$417K – 371
2024
Q3 		$417K Buy
6,239
+47
+0.8% +$4.32K 0.03% 200
2024
Q2 		$735K Buy
6,192
+67
+1% +$8.48K 0.06% 154
2024
Q1 		$653K Buy
6,125
+126
+2% +$12.7K 0.06% 165
2023
Q4 		$597K Buy
5,999
+153
+3% +$12.9K 0.06% 165
2023
Q3 		$604K Sell
5,846
-200
-3% -$22.3K 0.07% 156
2023
Q2 		$735K Buy
6,046
+62
+1% +$8.27K 0.07% 150
2023
Q1 		$919K Buy
5,984
+254
+4% +$41.9K 0.1% 133
2022
Q4 		$1.03M Buy
5,730
+179
+3% +$29.3K 0.13% 126
2022
Q3 		$656K Sell
5,551
-79
-1% -$12K 0.09% 143
2022
Q2 		$804K Buy
5,630
+2,774
+97% +$397K 0.1% 134
2022
Q1 		$492K Sell
2,856
-2,486
-47% -$419K 0.06% 159
2021
Q4 		$1.36M Buy
+5,342
New +$1.56M 0.16% 111

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Bristlecone Advisors's MRNA Position: Q4 2024 in Review

Bristlecone Advisors sold out of Moderna (MRNA) in Q4 2024, closing a stake of 6,239 shares — an estimated $417K sold.

Bristlecone Advisors first reported a position in MRNA in Q4 2021 and held it in 12 quarters. The position peaked at $1.36M in Q4 2021. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Bristlecone Advisors reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Bristlecone Advisors sold 6,239 Moderna shares in Q4 2024, an estimated $417K.
  • Bristlecone Advisors first reported a position in Moderna in Q4 2021 and held it in 12 quarters.
  • Bristlecone Advisors's Moderna position peaked at $1.36M in Q4 2021.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Bristlecone Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.